The Cytometry and Antibody Technology (CAT) Facility serves the University of Chicago Comprehensive Cancer Center (UCCCC) membership by providing all of the tools necessary to measure properties of cells and their products. The Fitch Monoclonal Subcore (FMS) develops the reagents used to label the cells, whereas the Flow Cytometry Subcore (FCS) provides the technology and staff expertise to use these reagents for experimental measurements. During the past 35 years, antibodies have become reliable and necessary tools in the continuously growing interdisciplinary approach to basic and clinical research, as well as the diagnosis, and treatment of disease. Antibody technology and its usage have evolved concurrently with flow and image cytometry and has become the dominant tool for the identification and classification of cells and cellular products, especially in the areas of cancer research. The Facility is utilized by UCCCC investigators in many areas of study involved in the basic and translational research of cellular phenotype and function.
The specific aim of the CAT Facility is to provide instrumentation and antibodies for the analytical detection of subcellular components and proteins using a range of fluorescence and non-fluorescence-based detection technologies. Further, the CAT Facility is designed to meet the wide-spread needs for specialized cytometric analysis and continues to respond to the demand for new and improved technology. Among these improvements include an expanding Antibody/Hybridoma Bank that provides commonly used, highest quality purified antibodies, pre-titered conjugated antibodies for flow cytometry, and hybridoma lines to UCCCC investigators. Cytometric technology improvements include the latest in high-speed cell sorting, multi-laser analyzers for performing polychromatic flow cytometry. Image-based cytometers, and bead-based analyte detectors.
Flow Cytometry technology and fluorescently labeled antibodies are the predominant tools utilized in the study and diagnosing of various cancers, including leukemias and lymphomas. Nearly every cancer-related research project utilizes these technologies in one form or another making them and their related services, indispensible to the future of cancer prevention and treatment.
|Zeineddine, Hussein A; Girard, Romuald; Saadat, Laleh et al. (2018) Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest :|
|Kane, Melissa; Deiss, Felicity; Chervonsky, Alexander et al. (2018) A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses. J Virol 92:|
|Xiao, Annie; Crosby, Jennie; Malin, Martha et al. (2018) Single-institution report of setup margins of voluntary deep-inspiration breath-hold (DIBH) whole breast radiotherapy implemented with real-time surface imaging. J Appl Clin Med Phys 19:205-213|
|Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733|
|Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721|
|Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4|
|Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48|
|Pu, Jinyue; Kentala, Kaitlin; Dickinson, Bryan C (2018) Multidimensional Control of Cas9 by Evolved RNA Polymerase-Based Biosensors. ACS Chem Biol 13:431-437|
|Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898|
|Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1|
Showing the most recent 10 out of 668 publications